CareDx Launches HeartCare® for Heart Transplant Recipients
HeartCare includes both AlloMap and AlloSure-Heart results for a holistic view into the health of a heart transplant patient. Clinical validity data for HeartCare will be presented at the International Society for Heart and Lung Transplantation (ISHLT) Annual 2018 Annual Meeting in
“HeartCare gives physicians and patients access to otherwise invisible information, indicators of both their immune system activity and graft health," said
Hannah Valantine, M.D., M.R.C.P., Senior Investigator, National Heart, Lung and Blood Institute, National Institutes of Health Kiran Khush, M.D., M.A.S., Associate Professor of Cardiovascular Medicine, Stanford University Medical Center Jon Kobashigawa, M.D., Thomas D. Gordon Professor of Medicine, and Director of the Heart Transplant Program, Cedars-Sinai Smidt Heart Institute Shelley Hall, M.D., Chief of Transplant Cardiology, Baylor University Medical Center
Four clinical abstracts featuring AlloMap or AlloSure-Heart will be presented by the study investigators:
Title: Donor-Derived Cell-Free DNA in D-OAR, a Real World, Clinical Use Heart Transplant Population
Title: Patterns of Gene Expression in High GEP Score Samples Correlated with Clinical Factors in the Outcomes AlloMap Registry
Title: Contribution of Individual Genes to Longitudinal Variation of Gene Expression Profile Scores
Title: Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap® Registry
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding our launch of HeartCare, as well as HeartCare’s prospects. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.